Published in Histopathology on September 01, 2010
uPAR-targeted optical imaging contrasts as theranostic agents for tumor margin detection. Theranostics (2013) 0.98
Targeting uPAR with antagonistic recombinant human antibodies in aggressive breast cancer. Cancer Res (2013) 0.91
uPAR-targeted optical near-infrared (NIR) fluorescence imaging and PET for image-guided surgery in head and neck cancer: proof-of-concept in orthotopic xenograft model. Oncotarget (2017) 0.84
Expression of uPAR in tumor-associated stromal cells is associated with colorectal cancer patient prognosis: a TMA study. BMC Cancer (2014) 0.83
Identification of cell-surface markers for detecting breast cancer cells in ovarian tissue. Arch Gynecol Obstet (2016) 0.80
Interleukin-like epithelial-to-mesenchymal transition inducer activity is controlled by proteolytic processing and plasminogen-urokinase plasminogen activator receptor system-regulated secretion during breast cancer progression. Breast Cancer Res (2014) 0.77
uPAR Expression Pattern in Patients with Urothelial Carcinoma of the Bladder--Possible Clinical Implications. PLoS One (2015) 0.75
A retrospective study of urokinase-type plasminogen activator receptor (uPAR) as a prognostic factor in cancer of the uterine cervix. Int J Clin Oncol (2014) 0.75
The head nodding syndrome--clinical classification and possible causes. Epilepsia (2008) 2.74
HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing. Virchows Arch (2010) 2.72
Budesonide is effective in treating lymphocytic colitis: a randomized double-blind placebo-controlled study. Gastroenterology (2009) 2.16
Hematopoietic and nonhematopoietic cell tissue factor activates the coagulation cascade in endotoxemic mice. Blood (2010) 2.10
Protease-activated receptor-1 contributes to cardiac remodeling and hypertrophy. Circulation (2007) 1.97
Intravascular tissue factor initiates coagulation via circulating microvesicles and platelets. FASEB J (2003) 1.82
The origins of colorectal carcinoma: specific nomenclature for different pathways and precursor lesions. Dtsch Arztebl Int (2010) 1.55
Clonal evolution including partial loss of human leukocyte antigen genes favoring extramedullary acute myeloid leukemia relapse after matched related allogeneic hematopoietic stem cell transplantation. Transplantation (2012) 1.52
Eosinophils are a major intravascular location for tissue factor storage and exposure. Blood (2006) 1.45
Guanylate-binding protein-1 expression is selectively induced by inflammatory cytokines and is an activation marker of endothelial cells during inflammatory diseases. Am J Pathol (2002) 1.42
Clinical characteristics of people with head nodding in southern Tanzania. Trop Doct (2010) 1.32
Specificity profiling of seven human tissue kallikreins reveals individual subsite preferences. J Biol Chem (2006) 1.31
Vascular endothelial cadherin promotes breast cancer progression via transforming growth factor beta signaling. Cancer Res (2008) 1.29
Oral budesonide for maintenance treatment of collagenous colitis: a randomized, double-blind, placebo-controlled trial. Gastroenterology (2008) 1.25
The alpha and beta subunits of the metalloprotease meprin are expressed in separate layers of human epidermis, revealing different functions in keratinocyte proliferation and differentiation. J Invest Dermatol (2007) 1.23
Urokinase-type plasminogen activator (uPA) and its inhibitor PAI-I: novel tumor-derived factors with a high prognostic and predictive impact in breast cancer. Thromb Haemost (2004) 1.17
Overexpression of the human tissue kallikrein genes KLK4, 5, 6, and 7 increases the malignant phenotype of ovarian cancer cells. Biol Chem (2006) 1.13
Coronary artery disease in a Werner syndrome-like form of progeria characterized by low levels of progerin, a splice variant of lamin A. Am J Med Genet A (2011) 1.13
Prognostic relevance of uPAR-del4/5 and TIMP-3 mRNA expression levels in breast cancer. Eur J Cancer (2005) 1.10
DNA hypermethylation of PITX2 is a marker of poor prognosis in untreated lymph node-negative hormone receptor-positive breast cancer patients. Breast Cancer Res Treat (2007) 1.08
A longitudinal study on nodding syndrome--a new African epilepsy disorder. Epilepsia (2013) 1.05
The substrate degradome of meprin metalloproteases reveals an unexpected proteolytic link between meprin β and ADAM10. Cell Mol Life Sci (2012) 1.05
A subset of human dendritic cells in the T cell area of mucosa-associated lymphoid tissue with a high potential to produce TNF-alpha. J Immunol (2003) 1.03
Monoclonal gammopathy of undetermined significance and Russell body formation in Helicobacter pylori gastritis. Helicobacter (2006) 1.02
Suppression of rat breast cancer metastasis and reduction of primary tumour growth by the small synthetic urokinase inhibitor WX-UK1. Thromb Haemost (2005) 1.01
A morphogenetic concept of salivary duct regeneration and metaplasia. Virchows Arch (2001) 1.00
Analysis of the pancreatic tumor progression by a quantitative proteomic approach and immunhistochemical validation. J Proteome Res (2009) 0.99
Structures and specificity of the human kallikrein-related peptidases KLK 4, 5, 6, and 7. Biol Chem (2008) 0.99
Molecular mechanisms associated with chromosomal and microsatellite instability in sporadic glioblastoma multiforme. Oncology (2004) 0.99
Multicenter immunohistochemical ALK-testing of non-small-cell lung cancer shows high concordance after harmonization of techniques and interpretation criteria. J Thorac Oncol (2014) 0.98
Clinical utility of level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1. Expert Rev Mol Diagn (2010) 0.98
Natural and synthetic inhibitors of kallikrein-related peptidases (KLKs). Biochimie (2010) 0.97
Tissue factor as a link between wounding and tissue repair. Diabetes (2005) 0.97
Gene expression analysis of pancreatic cell lines reveals genes overexpressed in pancreatic cancer. Pancreatology (2005) 0.97
Crystal structures of human tissue kallikrein 4: activity modulation by a specific zinc binding site. J Mol Biol (2006) 0.96
Development and evaluation of peptidic ligands targeting tumour-associated urokinase plasminogen activator receptor (uPAR) for use in alpha-emitter therapy for disseminated ovarian cancer. Eur J Nucl Med Mol Imaging (2007) 0.96
Kallikrein-related peptidase 4: a new activator of the aberrantly expressed protease-activated receptor 1 in colon cancer cells. Am J Pathol (2010) 0.96
HIF-1α is a protective factor in conditional PHD2-deficient mice suffering from severe HIF-2α-induced excessive erythropoiesis. Blood (2012) 0.95
Urokinase receptor splice variant uPAR-del4/5-associated gene expression in breast cancer: identification of rab31 as an independent prognostic factor. Breast Cancer Res Treat (2007) 0.94
Molecular and functional interdependence of the urokinase-type plasminogen activator system with integrins. Biol Chem (2003) 0.94
Proteolytic regulation of the urokinase receptor/CD87 on monocytic cells by neutrophil elastase and cathepsin G. J Immunol (2004) 0.93
Urokinase-type plasminogen activator (uPA) and its receptor (uPAR): development of antagonists of uPA/uPAR interaction and their effects in vitro and in vivo. Curr Pharm Des (2003) 0.93
Identification of a novel urokinase receptor splice variant and its prognostic relevance in breast cancer. Thromb Haemost (2003) 0.93
High-affinity urokinase-derived cyclic peptides inhibiting urokinase/urokinase receptor-interaction: effects on tumor growth and spread. FEBS Lett (2002) 0.92
Analyzing the protease web in skin: meprin metalloproteases are activated specifically by KLK4, 5 and 8 vice versa leading to processing of proKLK7 thereby triggering its activation. Biol Chem (2010) 0.92
Characteristics of the level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1. Expert Rev Mol Diagn (2010) 0.92
Stromal cell-associated expression of kallikrein-related peptidase 6 (KLK6) indicates poor prognosis of ovarian cancer patients. Biol Chem (2012) 0.92
A novel function of junctional adhesion molecule-C in mediating melanoma cell metastasis. Cancer Res (2011) 0.92
The human fibrinolytic system is a target for the staphylococcal metalloprotease aureolysin. Biochem J (2008) 0.90
Fulminant liver failure following infection by Clostridium perfringens. Surg Infect (Larchmt) (2004) 0.90
Quantitative RT-PCR assays for the determination of urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 mRNA in primary tumor tissue of breast cancer patients: comparison to antigen quantification by ELISA. Int J Mol Med (2008) 0.89
Interplay of human tissue kallikrein 4 (hK4) with the plasminogen activation system: hK4 regulates the structure and functions of the urokinase-type plasminogen activator receptor (uPAR). Biol Chem (2006) 0.89
Impact of breast cancer subtypes and patterns of metastasis on outcome. Breast Cancer Res Treat (2015) 0.89
Chromosomal genotype in breast cancer progression: comparison of primary and secondary manifestations. Cell Oncol (2008) 0.88
Polyclonal antibodies against kallikrein-related peptidase 4 (KLK4): immunohistochemical assessment of KLK4 expression in healthy tissues and prostate cancer. Biol Chem (2010) 0.88
Rab31 expression levels modulate tumor-relevant characteristics of breast cancer cells. Mol Cancer (2012) 0.88
Structural basis of the zinc inhibition of human tissue kallikrein 5. J Mol Biol (2007) 0.87
Human herpesvirus 8 and angiosarcoma: analysis of 40 cases and review of the literature. Pathology (2005) 0.87
Synthesis, solution structure, and biological evaluation of urokinase type plasminogen activator (uPA)-derived receptor binding domain mimetics. J Med Chem (2002) 0.86
Overexpression of the urokinase receptor mRNA splice variant uPAR-del4/5 affects tumor-associated processes of breast cancer cells in vitro and in vivo. Breast Cancer Res Treat (2010) 0.86
Intravascular tissue factor pathway--a model for rapid initiation of coagulation within the blood vessel. Thromb Haemost (2003) 0.86
Prognostic significance of immunohistochemical RhoA expression on survival in pancreatic ductal adenocarcinoma: a high-throughput analysis. Hum Pathol (2008) 0.86
An Alu repeat-mediated genomic GCNT2 deletion underlies congenital cataracts and adult i blood group. Hum Genet (2011) 0.86
Syndrome of inappropriate antidiuretic hormone secretion (SIADH) induced by vinorelbine treatment of metastatic breast cancer. Onkologie (2007) 0.85
Cytogenetic and molecular genetic analyses of giant cell glioblastoma multiforme reveal distinct profiles in giant cell and non-giant cell subpopulations. Cancer Genet Cytogenet (2007) 0.85
Chymotryptic specificity determinants in the 1.0 A structure of the zinc-inhibited human tissue kallikrein 7. Proc Natl Acad Sci U S A (2007) 0.84
Differential diagnosis of salivary acinic cell carcinoma and adenocarcinoma (NOS). A comparison of (immuno-)histochemical markers. Pathol Res Pract (2002) 0.84
Protease inhibitors prevent plasminogen-mediated, but not pemphigus vulgaris-induced, acantholysis in human epidermis. Biol Chem (2003) 0.84
Clinical value of protein expression of kallikrein-related peptidase 7 (KLK7) in ovarian cancer. Biol Chem (2014) 0.84
Microsatellite instability and loss of heterozygosity in squamous cell carcinoma of the head and neck. Head Neck (2008) 0.83
Autologous transplantation of genetically modified iris pigment epithelial cells: a promising concept for the treatment of age-related macular degeneration and other disorders of the eye. Proc Natl Acad Sci U S A (2002) 0.83
A bioengineered 3D ovarian cancer model for the assessment of peptidase-mediated enhancement of spheroid growth and intraperitoneal spread. Biomaterials (2013) 0.83
Disease processes may be reflected by correlations among tissue kallikrein proteases but not with proteolytic factors uPA and PAI-1 in primary ovarian carcinoma. Biol Chem (2006) 0.83
Loss of expression of ZAC/LOT1 in squamous cell carcinomas of head and neck. Head Neck (2004) 0.82
Interaction of plasminogen activator inhibitor type-1 (PAI-1) with vitronectin. Eur J Biochem (2002) 0.82
Function and clinical relevance of kallikrein-related peptidases and other serine proteases in gynecological cancers. Crit Rev Clin Lab Sci (2014) 0.82
Activation of human pro-urokinase by unrelated proteases secreted by Pseudomonas aeruginosa. Biochem J (2010) 0.82
Downregulation of serine protease HTRA1 is associated with poor survival in breast cancer. PLoS One (2013) 0.82
Assessment of Urokinase-Type Plasminogen Activator and Its Inhibitor PAI-1 in Breast Cancer Tissue: Historical Aspects and Future Prospects. Breast Care (Basel) (2008) 0.82
Platelet tissue factor: to be or not to be. Thromb Res (2013) 0.82
Interdependence of kallikrein-related peptidases in proteolytic networks. Biol Chem (2010) 0.82
Quantitative reverse transcription-PCR assay for detection of mRNA encoding full-length human tissue kallikrein 7: prognostic relevance of KLK7 mRNA expression in breast cancer. Clin Chem (2006) 0.81
Induction of proliferation and differentiation of cultured urothelial cells on acellular biomaterials. BJU Int (2004) 0.81